Klyv Therapeutics has appointed Hanne Th. Bonge-Hansen as Chief Operating Officer (COO). She joins the company as it continues to grow its team and advance its work on new treatments for cardiac fibrosis and heart failure.
Hanne holds a PhD in organic chemistry and is also an EQE-qualified European Patent Attorney, with experience spanning drug development, intellectual property, and leadership. As COO, she will work across the company’s drug development programme and support the continued build-up of Klyv as an organisation.
Her appointment strengthens the team at an important stage in the company’s development, as Klyv advances its anti-fibrotic approach and prepares for the next phase of its work.